Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

被引:20
|
作者
Wulffelé, MG
Kooy, A
Lehert, P
Bets, D
Donker, AJM
Stehouwer, CDA
机构
[1] Bethesda Gen Hosp, Dept Internal Med, NL-7909 AA Hoogeveen, Netherlands
[2] FUCAM, Dept Stat, Fac Econ, Mons, Belgium
[3] E Merck Nederland BV, Clin Res & Dev, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands
[6] Univ Hosp Maastricht, Dept Med, Maastricht, Netherlands
关键词
blood pressure; metformin; randomized controlled trial; Type; 2; diabetes; 24-h ambulatory blood pressure monitoring;
D O I
10.1111/j.1464-5491.2005.01554.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We investigated in a double-blind study whether metformin reduces blood pressure (BP) in patients with Type 2 diabetes intensively treated with insulin. Methhods A total of 220 patients with Type 2 diabetes were asked to undergo 24-h ambulatory BP monitoring (24-h ABPM). One hundred and eighty-two gave informed consent. Eighty-nine were randomized to metformin and 93 to placebo. Thirty-five subjects dropped out (13 placebo, 22 metformin users); 147 patients underwent a second 24-h ABPM, 16 weeks after randomization. Results Systolic BP (SBP), diastolic BP (DBP), pulse BP (PP), mean BP (MP) and heart rate (HR) were measured as office BP measurements and as 24-h ABPM for 24-h, day and night. Office BP measurements did not differ significantly between the placebo- and metformin-treated groups for any BP measure, but showed a non-significant trend for SBP reduction with metformin use (mean baseline-adjusted difference, metformin minus placebo: -4.2 mmHg, 95% CI, -9.9 to +1.5; P = 0.15). The baseline-adjusted differences of the ambulatory measurements were -0.2 mmHg (95% CI, -2.9 to +2.6) for the 24-h SBP, and +1.1 mmHg (95% CI, -0.7 to +2.8) for the 24-h DBP. On the whole, BP differences between metformin- and placebo-treated groups were not statistically significant. The only significant difference was for night-time PP (baseline-adjusted difference: -2.2 mmHg; 95% CI, -4.2 to -0.2). These results were not different after adjustment for age and diabetes duration, or for (changes in) body mass index, glycated haemoglobin, insulin dose or plasma homocysteine. Conclusion Metformin does not significantly affect BP in patients with Type 2 diabetes intensively treated with insulin.
引用
收藏
页码:907 / 913
页数:7
相关论文
共 50 条
  • [31] 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes
    Christian Ott
    Susanne Jung
    Agnes Bosch
    Dennis Kannenkeril
    Kristina Striepe
    Roland Schmieder
    [J]. Artery Research, 2019, 25 (Suppl 1) : S35 - S35
  • [32] Does the Physical Activity Level Decrease after Starting Insulin in Type 2 Diabetes?
    Alexandre, Laure
    Pezzino, Sandrine
    Rigalleau, Vincent
    [J]. DIABETES, 2017, 66 : A195 - A195
  • [33] Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
    Monami, Matteo
    Colombi, Claudia
    Balzi, Daniela
    Dicembrini, Ilaria
    Giannini, Stefano
    Melani, Cecilia
    Vitale, Valentina
    Romano, Desiderio
    Barchielli, Alessandro
    Marchionni, Niccolo
    Rotella, Carlo Maria
    Mannucci, Edoardo
    [J]. DIABETES CARE, 2011, 34 (01) : 129 - 131
  • [34] Blood glucose self monitoring in insulin treated type 2 diabetes
    Schiel, R
    Müller, UA
    Rauchfuss, J
    Sprott, H
    Müller, R
    [J]. DIABETOLOGIA, 1998, 41 : A40 - A40
  • [35] Postprandial Blood Pressure Decrease in Patients with Type 2 Diabetes and Mild or Severe Cardiac Autonomic Dysfunction
    Hashizume, Masahiko
    Kinami, Saori
    Sakurai, Keiichi
    Izawa, Kazuhiro P.
    Shiotani, Hideyuki
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (05)
  • [36] Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
    Hermann, LS
    Kalén, J
    Katzman, P
    Lager, I
    Nilsson, A
    Norrhamn, O
    Sartor, G
    Ugander, L
    [J]. DIABETES OBESITY & METABOLISM, 2001, 3 (06): : 428 - 434
  • [37] Vitamin D as a modulating agent of metformin and insulin in patients with type 2 diabetes
    Abdi, Fatemeh
    Movahedi, Monireh
    Alavi Nikje, Mir Mohammad
    Ghanei, Laleh
    Mirzaie, Sako
    [J]. JOURNAL OF RESEARCH IN PHARMACY, 2019, 23 (03): : 360 - 378
  • [38] Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes
    Juurinen, L.
    Tiikkainen, M.
    Saltevo, J.
    Nikkila, K.
    Lanki, H.
    Leppavuori, E.
    Kock, T.
    Teikari-Myyra, T.
    Kauppinen-Makelin, R.
    Kotronen, A.
    Yki-Jarvinen, H.
    [J]. DIABETIC MEDICINE, 2009, 26 (04) : 409 - 415
  • [39] Insulin-metformin combination therapy in obese patients with type 2 diabetes
    Jaber, LA
    Nowak, SN
    Slaughter, RR
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (01): : 89 - 94
  • [40] Efficacy and safety of dapagliflozin in patients with type 2 diabetes on insulin ± metformin regimens
    Yeh, H.
    Katz, A.
    [J]. DIABETOLOGIA, 2015, 58 : S357 - S357